Groundbreaking Longevity Supplement, Fatty15, Catapults Seraphina Therapeutics to Inc. 5000's Fifth Fasting-Growing Consumer Products Company in America

A new C15:0 supplement, with benefits discovered while helping older Navy dolphins, garners a top spot to tangibly meet consumers' demand for healthy aging solutions

SAN DIEGO, Aug. 12, 2025 /PRNewswire/ -- A once-in-a-century discovery made while helping older Navy dolphins has catapulted Seraphina Therapeutics and fatty15, a groundbreaking C15:0 supplement, as leaders in the longevity supplement space.

Inc., the leading media brand and playbook for the entrepreneurs and business leaders shaping our future, today announced that Seraphina Therapeutics, Inc. is the 5th fastest-growing private consumer product company in America on the Inc. 5000 list, the most prestigious ranking of the fastest-growing private companies in America. The list provides a data-driven snapshot of the most successful companies within the economy's most dynamic segment—its independent, entrepreneurial businesses. Past honorees include companies such as Microsoft, Meta, Chobani, Under Armour, Timberland, Oracle, and Patagonia. Among all private companies in America on the Inc. 5000 list, Seraphina ranked 117, which is among the top 2%.

"We are proud to be among the top of the fastest growing companies in America, furthering our global mission to deliver science-backed healthy aging solutions that meaningfully improve people's lives within months," says Dr. Eric Venn-Watson, Seraphina's Co-Founder and Co-CEO. "From helping Navy dolphins to improving global health - we couldn't have asked for a more fulfilling journey." Seraphina is led by Co-Founders Dr. Eric and Stephanie Venn-Watson, a husband-and-wife, physician-and-veterinarian military family duo of entrepreneurs.

An unexpected healthy aging discovery in older dolphins. While serving as a veterinary epidemiologist for the U.S. Navy, Dr. Stephanie Venn-Watson discovered that 1 in 3 older Navy dolphins were developing aging-associated conditions, including insulin resistance, chronic inflammation, elevated cholesterol, fatty liver disease, and anemia. Her team used metabolomics to discover that C15:0 (pentadecanoic acid), among hundreds of serum-based molecules, was the strongest predictor of the healthiest aging dolphins. The same outcomes have also been found in humans.

Building, robust science & Seraphina's leadership in longevity. Fast forward 10 years, 60+ patents, and 100+ peer-reviewed studies later, and C15:0 has emerged as the first essential fatty acid to be discovered in over 90 years. The robust science behind C15:0's essential role in longevity and healthy aging for humans (and dolphins) is the topic of a TEDx talk and the recently released and best-selling Simon & Schuster book, The Longevity Nutrient, authored by S. Venn-Watson. For her groundbreaking discoveries around C15:0, including the detailed pathophysiology of a nutritional C15:0 deficiency syndrome that may be impacting as many as 1 in 3 people globally, S. Venn-Watson has been recognized as a 2025 CNBC Changemaker.

As a result of the strong science behind C15:0's healthy aging benefits, the Office of Naval Research funded the Venn-Watsons to develop a pure, bioavailable and optimized C15:0 ingredient to help strengthen cell membranes against age-related breakdown. The result is fatty15, a pure C15:0 healthy aging supplement launched by the Venn-Watsons' startup, Seraphina Therapeutics, in the direct-to-consumer market in January 2021. Controlled clinical trials have since supported that increased C15:0 intake improves liver and red blood cell function, lowers LDL cholesterol, improves gut microbiome, lowers anxiety, and improves vascular function within 12 weeks. Further, among over 3,900 fatty15 customers surveyed, 70% reported health benefits within 16 weeks, including deeper sleep, calmer mood, less joint pain and improved blood labs.

Rapid customer growth, paired with high retention. Since its launch in January 2021, fatty15 has maintained a 95% monthly customer retention rate and currently has over 100,000 active subscribers. Fatty15's robust direct-to-consumer performance, coupled with more recent expansions into the Amazon.com and healthcare provider channels, have led to Seraphina's 3,031% growth from 2021 to 2024.

Sparking a global healthy aging movement. "We are incredibly grateful to the Navy and the Navy's dolphins for helping us unlock a core evolutionary tool of longevity that truly supports long-term wellness and healthy aging at all stages of life," says Dr. Stephanie Venn-Watson, Seraphina's Co-CEO. "Our discovery of C15:0 as an essential nutrient is proof that there are still simple and wholly meaningful discoveries to be made that can improve the health of all."

In addition to this most recent Inc. 5000 accolade, fatty15 has been recognized as a 2023 and 2024 Fast Company World Changing Idea in Wellness, Mindful Awards 2024 and 2025 Best Overall Supplement, 2025 Wellbeing Award for Best Breakthrough Supplement, Newsweek 2024 Readers' Choice Award for Best Supplement Brand, and Nutritional Outlook's Best of the Industry Award as an Ingredient Supplier.

"Making the Inc. 5000 is always a remarkable achievement, but earning a spot this year speaks volumes about a company's tenacity and clarity of vision," says Mike Hofman, editor-in-chief of Inc. "These businesses have thrived amid rising costs, shifting global dynamics, and constant change. They didn't just weather the storm—they grew through it, and their stories are a powerful reminder that the entrepreneurial spirit is the engine of the U.S. economy."

About Seraphina Therapeutics, Inc.: Seraphina Therapeutics, Inc. is a health and wellness company dedicated to advancing global health through the discovery of essential fatty acids and micronutrient therapeutics. Through rigorous breakthrough science, the company develops fatty acid supplements, food fortifiers, and nutritional interventions to strengthen cells, keep mitochondria working, and advance cellular homeostasis to counter age-related breakdown. With its team of industry-leading scientists, Seraphina Therapeutics challenges long-held approaches to nutrition, enabling the creation of novel health products designed to support quality of life. For more information, please visit DiscoverC15.com and fatty15.com.

Media Contact:
Fatty15 Press Office
Fatty15
1 619-407-9225
[email protected]
https://www.fatty15.com

SOURCE Seraphina Therapeutics